Neurotransmitter Markers of Depression *

Abstract

The role of antidepressants in bringing about adaptive changes in peripheral and central neurotransmitter receptors is briefly reviewed and extended to show how changes in platelet and lymphocyte adrenoceptor and serotonin receptor activity may correlate with the depressed state and normalise following effective treatment. By contrast, the ³H-imipramine binding sites on the platelet membrane do not change following successful treatment and may therefore reflect a trait-dependent (genetic) change. The neuroendocrine markers, such as the dexamethasone suppression test (DST), have the advantage over the receptor markers in that they require less sophisticated laboratory facilities. It is concluded that a better insight into the aetiology and progress of depression may be gained by combining receptor markers with such neuroendocrine markers as the DST.

References

Hollister

L. E.

Treatment of depression. Ann Int Med 1978;89: 78–84.

Goldberg

Huxley

Mental illness in the community. London, Tavistock, 1980.

Watts

C. A. H.

Depressive disorders in the community. Bristol, John Wright, 1965.

Carr

A. C.

Ancill

R. J.

Ghosh

Margo

Direct assessment of depression by micro computer. Acta Psychiat Scand 1981;64: 415–422.

Schildkraut

J. J.

Orsulak

P. J.

Schatzberg

A. F.

Towards a biochemical classification of depressive disorders 1. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depression. Arch Gen Psychiat 1978;35: 1427–1433.

van Praag

de Hahn

Central serotonin metabolism and frequency of depression. Psychiat Res 1979;1: 219–224.

Leonard

B. E.

Current status of the biogenic amine theory of depression. Neurochem Int 1982;4: 339–350.

Montgomery

S. A.

The non-selective effect of selective antidepressants. Adv Biochem Psychopharmac 1982;31: 49–56.

Veith

R. C.

Bielski

R. J.

Bloom

Urinary MHPG excretion and treatment with desipramine or amitripthline: prediction of response, effect of treatment and methodological hazards. J Clin Psychopharmac 1983;3: 18–27.

10.

Wyatt

R. J.

Portnoy

Kupfer

D. J.

Resting plasma catecholamine concentrations in patients with depression and anxiety. Arch Gen Psychiat 1971;24: 65–70.

11.

Shimizu

Fujita

Effects of β-adrenergic receptor blocking agents in depression as measured by plasma noradrenaline concentration and blood pressure. In: Langer

S. Z.

ed. New vistas in depression. New York, Pergamon Press, 1981.

12.

Luck

Mikhailidis

D. P.

Dashwood

M. R.

Platelet hyperaggregability and increased α-adrenoceptor density in anorexia nervosa. Clin Endocrinol Metab 1983;57: 911–914.

13.

Raisman

Briley

M. S.

Langer

S. Z.

Specific tricyclic antidepressant binding sites in rat brain. Nature 1979;281: 148–149.

14.

Langer

S. Z.

Zarifian

Briley

High-affinity binding of 3H-imipramine in brain and platelets and its relevance to the biochemistry of affective disorders. Life Sci 1981;29: 211–218.

15.

Vetulani

Stawarz

R. J.

Dingell

J. V.

A possible common mechanism of action of antidepressant treatments. NS Arch Pharmac 1976;293: 109–114.

16.

Kant

G. J.

Bates

V. E.

Lenox

R. A.

Effects of acute and chronic desemethylimipramine on levels of cyclic AMP in vivo. Biochem Pharmac 1983;32: 732–735.

17.

Sulser

Janowsky

A. J.

Okada

Regulation of recognition and action function of the norepinephrine receptor-coupled adenylate cyclase system in brain: implications for the therapy of depression. Neuropharmac 1983;22: 425–431.

18.

Starke

Regulation of noradrenaline release by pre-synaptic receptor systems. Rev Physiol Biochem Pharmac 1977;77: 1–24.

19.

Pletscher

Platelets as models for monoaminergic neurons. In: Essays in neurochemistry and neuropharmacology. Basel, Karger, 1975; Vol. 4:328–342.

20.

Davies

I. B.

Mathias

C. J.

Sudera

Agonist regulation of α-adrenergic receptors in man. J Cardiovasc Pharmac 1982;4:S138–S140.

21.

Jung

R. T.

Shetty

P. S.

Barrand

Role of catecholamines in hypotensive response to dieting. Br Med J 1979;1: 12–24.

22.

Lampugnani

M. G.

de Gaetano

Comparative effects of ketanserin, a novel serotonergic receptor antagonist, on 5-HT induced shape change and 5-HT uptake in rat and human platelets. Biochem Pharmac 1982;31: 3000–3002.

23.

Healy

Carney

P. A.

Leonard

B. E.

Monoamine-related markers of depression: changes following treatment. J Psychiat Res 1983;17: 251–260.

24.

Wirz-Justice

Campbell

I. C.

Antidepressant drugs can slow or dissociate circadian rhythms. Experientia 1982;38: 1301–1309.

25.

Kafka

M. S.

Wirz-Justice

Naber

Effect of lithium on circadian neurotransmitter receptor rhythms. Neuropsychobiol 1982;8: 41–50.

26.

Goodwin

F. K.

Wirz-Justice

Wehr

T. A.

Evidence that the pathophysiology of depression and the mechanism of action of antidepressant drugs both involve alterations in circadian rhythms. Adv Biochem Psychopharmac 1982;31: 1–11.

27.

Mendlewicz

van Praag

H. M.

(eds.). Biological rhythms and behaviour. Adv Biol Psychiat 1983; 11.

28.

Olpe

H. R.

Molecular view of the treatment of depression. In: Korf

Pepplinkhuizen

(eds.) Depression: molecular and psychologically based therapies. TGO Drachten, Holland, TGO Foundation, 1983; 21–45.

29.

Garrer

D. L.

Pandey

S. N.

Dekirmenjian

Growth hormones and catecholamines in affective disease. Am J Psychiat 1975;132: 1149–1154.

30.

Carroll

B. J.

Mendels

Neuroendocrine regulation in affective disorders. In: de Wied

(ed.) Hormones, behaviour and psychopathology. New York, Raven Press, 1976; 193–224.

31.

Meltzer

H. Y.

Fang

V. S.

Central determination and the dexamethasone suppression test. Arch Gen Psychiat 1983;40: 501–505.

32.

Asnis

G. M.

Sachar

E. J.

Halbreich

Cortisol secretion and dexamethasone response in depression. Am J Psychiat 1981;138: 1218–1221.

33.

Carroll

B. J.

Feinberg

Greden

J. F.

A specific laboratory test for the diagnosis of melancholia. Standardisation, validation and clinical utility. Arch Gen Psychiat 1981;38: 15–22.

34.

Ballin

Gottfries

C.-G.

Karlsson

Dexamethasone suppression test and serum prolactin in dementia disorders. Br J Psychiat 1983;143: 277–281.

35.

Brambilla

Smeraldi

Sacchetti

Deranged anterior pituitary responsiveness to hypothalamic hormones in depressed patients. Arch Gen Psychiat 1978;35: 1231–1238.

36.

Matussek

Romisch

Ackenheil

M. Mhpg

Excretion during sleep deprivation in endogenous depression. Neuropsychobiol 1977;3: 23–29.

37.

Langer

Heinze

Reim

Growth hormone response to d-amphetamine in normal controls and in depressed patients. Neurosci Lett 1975;1: 185–189.

38.

Tuomisto

Rukiainen

Ahlfors

U. G.

Decreased uptake of 5-hydroxytryptamine in blood platelets from patients with endogenous depression. Psychopharmac 1979;65: 141–147.

39.

Boullin

D. J.

Glenton

P. A. M.

Characterisation of receptors mediating 5-HT and catecholamine induced platelet aggregation assessed by the actions of α and β-blockers, butyrophenones, 5-HT antagonists and chlorpromazine. Br J Pharmac 1978;62: 537–542.

40.

Kafka

M. S.

Smith

C. C.

Alpha-adrenergic receptors on human platelets. Life Sci 1977;21: 1429–1438.

41.

Williams

L. T.

Lefkowitz

R. J.

Identification of β-adrenergic receptors in human lymphocytes by 3H-alprenolol binding. J Lab Clin Med 1976;57: 149–155.

42.

Wagner

H. R.

Crutcher

K. A.

Davis

J. N.

Chronic estrogen treatment decreases β-adrenergic responses in rat cerebral cortex. Brain Res 1979;171: 147–151.